Physician profile
Marina Alper
NPI 1609817337
$7,791.64
in general payments reported to CMS, 2019-2025
30 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $604 · 2021: $770 · 2022: $1,350 · 2023: $784 · 2024: $920 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,568.15 | 2019-2025 | Mavyret, Creon |
| Glaxosmithkline, LLC. | $570.64 | 2019-2025 | Bexsero, Penmenvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $519.13 | 2019-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $365.00 | 2024-2025 | Rezdiffra |
| Pfizer INC. | $300.29 | 2019-2025 | |
| Incyte Corporation | $245.90 | 2024-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $243.00 | 2023-2025 | Dupixent |
| Cranial Technologies, INC | $224.24 | 2021-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $185.43 | 2019-2025 | Gardasil 9, Gardasil, Enflonsia |
| Sanofi Pasteur INC. | $182.48 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $170.05 | 2021 | |
| Sobi, INC | $135.67 | 2019-2024 | |
| Mirum Pharmaceuticals, INC. | $127.02 | 2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $121.88 | 2024 | Bylvay |
| Nestle Healthcare Nutrition INC. | $112.81 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $109.08 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $107.14 | 2022 | |
| Corium, LLC | $81.26 | 2022-2024 | Azstarys |
| Novo Nordisk INC | $76.31 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $74.24 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.96 | 2025 | Xifaxan |
| Phadia US INC. | $48.38 | 2022-2025 | Immunocap |
| Boston Scientific Corporation | $31.18 | 2021-2022 | |
| Abbott Laboratories | $26.43 | 2019 | |
| Becton, Dickinson and Company | $20.20 | 2020 | |
| Neos Therapeutics, LP | $19.23 | 2019 | |
| Hologic Sales and Service, LLC | $18.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.35 | 2019 | |
| Seqirus USA INC | $14.12 | 2025 | Flucelvax |
| Ironshore Pharmaceuticals INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Alper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.